PP / MONOGRAPH 095 Peptide or related research compound

Thymosin Alpha-1

Discovery history, preclinical evidence, human studies, current FDA context, and the questions that still need to be answered.

Evidence is not equivalence.

Research on a named molecule does not establish that a catalog material is the studied drug product. Identity, sequence, salt, formulation, purity, sterility, route, labeling, and indication can change the scientific and regulatory conclusion.

ORIGIN / HISTORY

When was Thymosin Alpha-1 first described?

Thymosin alpha-1 was isolated from thymosin fraction 5 and sequenced by Allan Goldstein and colleagues in the 1970s; a primary report appeared in 1977. [1]

PRECLINICAL EVIDENCE

What do animal and laboratory studies show?

Preclinical pharmacology may exist, but this registry does not treat animal or in-vitro findings as human outcomes. The literature map should be reviewed for the model, species, comparator, endpoint, and replication status. [2]

Translation limitCell and animal findings can generate mechanisms and safety signals, but they do not predict clinical benefit on their own.

CLINICAL EVIDENCE

Are there human studies?

Approved in many countries (Zadaxin); studied in COVID, hepatitis, oncology. These findings apply only to the studied drug product, formulation, population, route, dose, and indication. [2][3]

Check the live study registry ↗

U.S. REGULATORY STATUS

Is Thymosin Alpha-1 FDA cleared or approved?

Drug terminology: FDA generally approves drug products; “clearance” is typically a medical-device pathway.

FDA’s current compounding materials identify safety or evidence concerns relevant to Thymosin Alpha-1 or a related named substance. Category or nomination status is not drug approval. This page does not identify an FDA-approved product corresponding to this catalog name; verify current records directly with FDA. [4][5][6]

RESEARCH OUTLOOK

Where is the scientific promise?

The credible research opportunity for Thymosin Alpha-1 is to define which findings reproduce across adequately powered trials, which endpoints are clinically meaningful, and how benefit–risk changes by indication and formulation. Existing human evidence cannot establish equivalence to an unverified catalog material. [2][3]

LIMITATIONS / PRECAUTIONS

What should professionals keep in view?

Not FDA-approved in the United States; injection reactions and product-quality uncertainty. FDA's current compounding page identifies safety and evidence limitations; nomination status is not approval. [2]

Professional-use boundary

This page does not provide a diagnosis, treatment recommendation, protocol, dose, reconstitution instruction, route, or administration schedule. Any lawful program requires independent regulatory, quality, toxicology, and clinical review.

SOURCE REGISTER

References and live evidence maps

Primary papers support specific historical claims where available. PubMed and ClinicalTrials.gov links are live evidence maps, not proof that every result applies to the exact catalog material. FDA links should be rechecked because regulatory pages and product labels can change.